Cargando…

Coordinated Actions of FXR and LXR in Metabolism: From Pathogenesis to Pharmacological Targets for Type 2 Diabetes

Type 2 diabetes (T2D) is the most prevalent metabolic disease, and many people are suffering from its complications driven by hyperglycaemia and dyslipidaemia. Nuclear receptors (NRs) are ligand-inducible transcription factors that mediate changes to metabolic pathways within the body. As metabolic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Lin, Pang, Shuguang, Sun, Yongmei, Tian, Yuling, Yu, Li, Dang, Ningning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020365/ https://www.ncbi.nlm.nih.gov/pubmed/24872814 http://dx.doi.org/10.1155/2014/751859

Ejemplares similares

Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH
por: Cariello, Marica, et al.
Publicado: (2021)

Dissociation of Intestinal and Hepatic Activities of FXR and LXRα Supports Metabolic Effects of Terminal Ileum Interposition in Rodents
por: Mencarelli, Andrea, et al.
Publicado: (2013)

Berberine Promotes OATP1B1 Expression and Rosuvastatin Uptake by Inducing Nuclear Translocation of FXR and LXRα
por: Liu, Mingyi, et al.
Publicado: (2020)

Encapsulation of LXR ligand by D-Nap-GFFY hydrogel enhances anti-tumorigenic actions of LXR and removes LXR-induced lipogenesis
por: Feng, Ke, et al.
Publicado: (2021)

Pioneer factor Foxa2 enables ligand-dependent activation of type II nuclear receptors FXR and LXRα
por: Kain, Jessica, et al.
Publicado: (2021)

Gamma-Muricholic Acid Inhibits Nonalcoholic Steatohepatitis: Abolishment of Steatosis-Dependent Peroxidative Impairment by FXR/SHP/LXRα/FASN Signaling
por: Xie, Yang, et al.
Publicado: (2023)

Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR
por: Jadhav, Kavita, et al.
Publicado: (2018)

System analysis of cross-talk between nuclear receptors reveals an opposite regulation of the cell cycle by LXR and FXR in human HepaRG liver cells
por: Wigger, Leonore, et al.
Publicado: (2019)

Activation of FXR by obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR
por: Dong, Bin, et al.
Publicado: (2019)

The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR/FXR dual receptor activator
por: Shiragannavar, Varsha D., et al.
Publicado: (2023)

Quantitative proteomic study of the plasma reveals acute phase response and LXR/RXR and FXR/RXR activation in the chronic unpredictable mild stress mouse model of depression
por: Yang, Chuangchuang, et al.
Publicado: (2018)

Multi-Omics Analysis Reveals Up-Regulation of APR Signaling, LXR/RXR and FXR/RXR Activation Pathways in Holstein Dairy Cows Exposed to High-Altitude Hypoxia
por: Kong, Zhiwei, et al.
Publicado: (2019)

LXRα and LXRβ Nuclear Receptors Evolved in the Common Ancestor of Gnathostomes
por: Fonseca, Elza, et al.
Publicado: (2017)

Transcriptional coordination of hepatic autophagy by nutrient-sensing nuclear receptor PPARα and FXR
por: Lee, Jae Man
Publicado: (2016)

FXR induces SOCS3 and suppresses hepatocellular carcinoma
por: Guo, Fei, et al.
Publicado: (2015)

Bioenergetic cues shift FXR splicing towards FXRα2 to modulate hepatic lipolysis and fatty acid metabolism
por: Correia, Jorge C., et al.
Publicado: (2015)

Bile Acids, FXR, and Metabolic Effects of Bariatric Surgery
por: Noel, Olivier F., et al.
Publicado: (2016)

The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD
por: Dixon, Emmanuel D., et al.
Publicado: (2021)

FXR-Mediated Cortical Cholesterol Accumulation Contributes to the Pathogenesis of Type A Hepatic Encephalopathy
por: McMillin, Matthew, et al.
Publicado: (2018)

Thrombomodulin activation driven by LXR agonist attenuates renal injury in diabetic nephropathy
por: Wang, Wei, et al.
Publicado: (2023)

Identfication of Potent LXRβ-Selective Agonists without LXRα Activation by In Silico Approaches
por: Chen, Meimei, et al.
Publicado: (2018)

Disruption of Adipose Tissue Metabolism by Glucocorticoids Is Attenuated With LXRβ Antagonism
por: Li, Jia Xu, et al.
Publicado: (2021)

Mongolian medicine in treating type 2 diabetes mellitus combined with nonalcoholic fatty liver disease via FXR/LXR-mediated P2X7R/NLRP3/NF-κB pathway activation
por: Bao, Shuyin, et al.
Publicado: (2022)

Fxr signaling and microbial metabolism of bile salts in the zebrafish intestine
por: Wen, Jia, et al.
Publicado: (2021)

SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
por: Zhou, Jiyu, et al.
Publicado: (2020)

Commentary: Can FXR serve as a potential target for COVID-19 prevention?
por: Pang, Juan, et al.
Publicado: (2023)

miR-206 controls LXRα expression and promotes LXR-mediated cholesterol efflux in macrophages
por: Vinod, Manjula, et al.
Publicado: (2014)

Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease
por: Nijmeijer, Rian M., et al.
Publicado: (2011)

FXR an emerging therapeutic target for the treatment of atherosclerosis
por: Mencarelli, Andrea, et al.
Publicado: (2010)

Update on FXR Biology: Promising Therapeutic Target?
por: Han, Chang Yeob
Publicado: (2018)

FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach
por: Lu, Weiqiang, et al.
Publicado: (2015)

NRF2 Activation in Autophagy Defects Suppresses a Pharmacological Transactivation of the Nuclear Receptor FXR
por: Kim, Eun Young, et al.
Publicado: (2022)

Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study
por: Jose, Sandra, et al.
Publicado: (2023)

Establishment of a monoclonal antibody for human LXRα: Detection of LXRα protein expression in human macrophages
por: Watanabe, Yuichiro, et al.
Publicado: (2003)

Reconstruction of FXR Beam Conditions
por: Nexsen, W E, et al.
Publicado: (2001)

Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases
por: Griffett, Kristine, et al.
Publicado: (2023)

The Effect of Simvastatin on Glucose Homeostasis in Streptozotocin Induced Type 2 Diabetic Rats
por: Wang, Lulu, et al.
Publicado: (2013)

Bile Acids and FXR: Novel Targets for Liver Diseases
por: Stofan, Mary, et al.
Publicado: (2020)

Targeting FXR and FGF19 to Treat Metabolic Diseases—Lessons Learned From Bariatric Surgery
por: Bozadjieva, Nadejda, et al.
Publicado: (2018)

SIRT1 activation synergizes with FXR agonism in hepatoprotection via governing nucleocytoplasmic shuttling and degradation of FXR
por: Cui, Shuang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_40ldc2komp2pge1b3i4opcgm6s